CA125 dominated performance for ovarian cancer early detection amongst four serum biomarkers evaluated in EPIC study pre-diagnostic serum, elevating on average 3 years prior to detection. Adding HE4 provided only marginal improvement. This natural history supports annual testing for early detection and highlights the importance of biomarker discovery complementing CA125.
- Received July 1, 2016.
- Accepted July 7, 2016.
- Copyright ©2016, American Association for Cancer Research.